What We Do

OUR APPROACH

border
Unique patterns, boundless pathways and infinite possibilities . . .
Adult living with Niemann-Pick disease type C
Adult living with Niemann-Pick disease type C

What We Do

border

Like the limitless, unique and manifold zebra-stripe patterns, we see complexity as a call to push further for the benefit of the rare disease community that we serve.

In the face of difficult diseases, we don’t see barriers — we see opportunities to think differently. By staying true to our strategic pillars and driven by the urgency of patient needs, we specialize in advancing promising medicines that face unique development paths.

Our experience working with patient advocacy groups has given us deeper insights into patients and care partners, the challenges they face and how best we can work together with the rare disease community. We believe this will enable us to design better clinical programs that put the patient first.

Employing strategies that are outside the box, we push boundaries beyond rigid, one-track drug development paths that can limit access to therapeutics for people with rare diseases.

Leveraging our decades of experience in drug development, we have the know-how to develop therapies faster and a track record of overcoming challenging regulatory situations.

As a science driven company, rather than fitting data to a pre-determined narrative, we employ a data-driven, scientific approach to development, assessing and re-assessing our strategy throughout the product development journey.

This commitment to data-driven decision making not only improves patient outcomes — it also establishes the foundation for building a leading, successful company.

Children living with Niemann-Pick disease type C
Children living with Niemann-Pick disease type c